Lymphadenectomy and Chemotherapy in Endometrial Cancer
Author Information
Author(s): Otsuka I, Kubota T, Aso T
Primary Institution: Tokyo Medical and Dental University Hospital
Hypothesis
The study aims to evaluate the therapeutic benefit of lymphadenectomy and adjuvant therapy, particularly chemotherapy, in endometrial carcinoma.
Conclusion
Lymphadenectomy may improve survival by removing macroscopically positive nodes, and chemotherapy is a suitable adjuvant therapy for endometrial carcinoma.
Supporting Evidence
- The 5-year survival rate for patients with lymph node metastasis was 60%, compared to 96% for those without.
- Adjuvant chemotherapy was administered to 46 patients, with 42 receiving a platinum-based regimen.
- Recurrence was observed in 14 patients, with the majority occurring in distant sites.
Takeaway
Doctors looked at how surgery and chemotherapy help women with a type of cancer called endometrial carcinoma. They found that surgery can help women live longer, especially when combined with chemotherapy.
Methodology
The study analyzed survival rates and recurrence patterns in 106 patients who underwent surgery with lymphadenectomy.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective and may not account for all variables affecting survival.
Participant Demographics
Patients ranged in age from 27 to 81 years, with a mean age of 56 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website